OTX-2002 is a gene therapy commercialized by Omega Therapeutics, with a leading Phase II program in Hepatocellular Carcinoma. According to Globaldata, it is involved in 1 clinical trial, which is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of OTX-2002’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

The revenue for OTX-2002 is expected to reach an annual total of $244 mn by 2039 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

OTX-2002 Overview

OTX-2002 is under development for the treatment of hepatocellular carcinoma and solid tumors, colorectal cancer, soft tissue sarcoma, cervical cancer, pancreatic cancer. The drug candidate is an epigenomic controller that comprises of a DNA-binding domain and an epigenetic effector domain delivered as mRNA via lipid nanoparticles (LNPs) to modulate the gene expression. It is administered through intravenous route. It acts by targeting oncogene MYC and is being developed based on OMEGA epigenomic programming platform.

Omega Therapeutics Overview

Omega Therapeutics is a biotechnology company that focuses on developing genomic medicines through epigenomic programming. The company is headquartered in Cambridge, Massachusetts, the US.

The company reported revenues of (US Dollars) US$2.1 million for the fiscal year ended December 2022 (FY2022). The operating loss of the company was US$102.8 million in FY2022, compared to an operating loss of US$66.2 million in FY2021. The net loss of the company was US$102.7 million in FY2022, compared to a net loss of US$68.3 million in FY2021. The company reported revenues of US$0.8 million for the third quarter ended September 2023, an increase of 9.5% over the previous quarter.

For a complete picture of OTX-2002’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 7 February 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.